Aurinia Pharmaceuticals Plunges 13.01% on Investor Sentiment Shift

Aurinia Pharmaceuticals Inc. experienced a significant drop of 13.01% in pre-market trading on April 10, 2025, reflecting a notable shift in investor sentiment towards the biopharmaceutical company.

Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing products for patients suffering from serious diseases with a high unmet medical need. The company is known for its investigational drug LUPKYNIS (voclosporin), which is being developed for the treatment of lupus nephritis (LN). Additionally, Aurinia is working on AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company derives a significant portion of its revenue from the United States.

The volatility of Aurinia Pharmaceuticals' stock is measured as the annualized standard deviation between monthly returns from the security over the past year. As of April 10, 2025, the company's volatility stands at 31.64%, indicating a higher level of risk compared to more stable securities. Volatility reflects the uncertainty or risk of a security’s value, with higher volatility suggesting wider fluctuations around the average price. This means the stock price can change dramatically in either direction within a short period, which is a key factor for investors to consider when evaluating the risk associated with Aurinia Pharmaceuticals' stock.